Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × vandetanib × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 5 gallium Ga 68 dotatate 3 3-Iodobenzylguanidine 3 Magnetic Resonance Spectroscopy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 vandetanib 1 olaparib 1 fludarabine phosphate 1 copper dotatate CU-64 1 cabozantinib 1 atezolizumab 1 Specimen Handling 1 Lutetium-177 1 Lutetium 1 Iodine-131 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Everolimus 1 Erlotinib Hydrochloride 1 Cyclophosphamide 1 Biopsy 1 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 1 3-fluorobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡